Core Viewpoint - Regenxbio announced positive interim data from an early-to-mid stage study of its experimental gene therapy for Duchenne muscular dystrophy, indicating continued improvement in patient outcomes [1] Group 1 - The study focuses on patients with Duchenne muscular dystrophy, a severe genetic disorder characterized by progressive muscle degeneration [1] - Interim results suggest that the gene therapy is showing promising efficacy, which could lead to significant advancements in treatment options for this patient population [1] - The company is likely to continue its research and development efforts based on these positive findings, potentially impacting its future market position [1]

Parents fought to bring back Sarepta’s $3.2 million Duchenne gene therapy after patient deaths forced it off the market https://t.co/QNaDu2uCWM ...